Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis

Bowen, Tom; Greenbaum, Joseph; Charbonneau, Yves; Hébert, Jacques; Filderman, Ronald; Sussman, Gordon; Carpio, Jaime Del; Gold, Milton; Keith, Paul K.; Moote, William; Cecchetto, Steve; Cecchetto, Ollie; Sharp, D.; Broutin, Olivier; André, C.

doi:10.1016/s1081-1206(10)61408-1

Cited by 66 publications

(50 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wilson et al (1698) published a Cochrane Collaboration meta-analysis of SLIT in rhinitis and proposed that it was safe and effective. The Cochrane meta-analysis (1699) was followed by several studies which accorded with the results of the review (1103,(1700)(1701)(1702)(1703)(1704)(1705)(1706)(1707)(1708)(1709)(1710)(1711). Moreover, pivotal trials have been carried out and the results on over 600 patients showed convincingly that in grass pollen allergy, SLIT is safe and effective using tablets (1103,1712).…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,861

1,761

View full text Add to dashboard Cite

Section: Sublingual Immunotherapymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,861

1,761

View full text Add to dashboard Cite

“…Several regimens have been employed including daily dosing [82,[122][123][124][125][126][127][128][129][130][131][132] with or without an initial updosing phase, three times per week [133] and weekly [134]. With seasonal allergens such as pollen, various regimens including pre-seasonal, co-seasonal, pre-or co-seasonal followed by perennial have been investigated.…”

Section: Dosing Schedules For Sublingual Immunotherapymentioning

confidence: 99%

Immunotherapy for allergic rhinitis

Walker¹,

Durham

Till

et al. 2011

Clin Experimental Allergy

147

125

View full text Add to dashboard Cite

SummaryAllergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality. This guidance prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) is for the management of AR in patients that have failed to achieve adequate relief of symptoms despite treatment with intranasal corticosteroids and/or antihistamines. The guideline is based on evidence and is for use by both adult physicians and paediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are indications and contraindications for immunotherapy, criteria for patient selection, the evidence for short-and long-term efficacy of subcutaneous and sublingual immunotherapy, and discussion on safety and the different modes of immunotherapy including, pre-seasonal and co-seasonal treatments. There are sections on children, allergen standardization, vaccines used in the United Kingdom, oral allergy syndrome, cost effectiveness of immunotherapy and practical considerations of undertaking immunotherapy including recommendations on who should undertake immunotherapy and dosing schedules. Finally, there is discussion on potential biomarkers of response to immunotherapy, the use of component-resolved diagnostics, novel approaches, alternative routes and potential areas for future research.Keywords aeroallergens, allergen, allergic rhinitis, allergen standardization, allergy to animals, allergy to house dust mites, asthma, BSACI, cat allergy, component-resolved diagnostics, cost effectiveness, dosing schedules, grass pollen, guideline, immunotherapy, oral allergy syndrome, perennial rhinitis, pollinosis, ragweed allergy, SAR, seasonal pollen induced rhinitis, subcutaneous immunotherapy, sublingual immunotherapy, tree pollen Submitted 19 February 2011; revised 6 May 2011; accepted 9 May 2011. Executive summaryUntreated rhinitis represents a major cause of morbidity that includes interference with usual daily activities and impaired sleep quality. Immunotherapy, both subcutaneous and sublingual, is an effective treatment for adults and children with severe allergic rhinitis (AR) that does not respond to conventional pharmacotherapy and allergen avoidance measures. The efficacy of immunotherapy depends on correct patient selection, the type of allergen and the product chosen for treatment. Each vaccine requires individual assessment before recommendation for routine use.

show abstract

“…The duration of SLIT courses varied from 3 months (minimum duration) to 3 years (maximum duration). The administration regimen was preseasonal in three studies (27,32,44), co-seasonal in three (15,42,47), and continuous in eight trials (30,35,38,39,41,43,46,54), despite the allergen was seasonal. In the remaining 27 trials the adopted regimen was precoseasonal.…”

Section: Literature Analysismentioning

confidence: 99%

Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?

Lombardi

Incorvaia²,

Braga

et al. 2009

Allergy

View full text Add to dashboard Cite

The modalities of administration of sublingual immunotherapy (SLIT), including dosing, build‐up phase, duration of the treatment, and frequency of the maintenance dose are largely variable. In the case of pollen (SLIT), the complexity increases, since preseasonal, coseasonal and pre‐coseasonal regimens can be used. The administration regimens are of relevance from a practical point of view, but can also have economic implications. We review herein the available literature (randomized double blind controlled studies) on pollen SLIT, in order to derive experimentally‐supported suggestions about the regimens of administration that should be preferred.

show abstract

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis

Cited by 66 publications

References 16 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Immunotherapy for allergic rhinitis

Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?

Contact Info

Product

Resources

About